(firstQuint)Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients.

 This study is randomized, double-blinded, and placebo-controlled.

 80 Patients will be enrolled and randomized to CSJ148 and placebo in a ratio of 3:1.

 Patients undergoing stem cell transplantation will be enrolled into the study.

 The study will consist of a screening period, a baseline visit, approximately 3-month treatment exposure period, an end-of-therapy visit, a follow-up period, and a study completion evaluation approximately 3.

5 months after the last dose of study drug is administered.

.

 Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients@highlight

This study is designed to test if CSJ148 can prevent HCMV replication after stem cell transplantation.

